Alexion, Complement co-develop CP010 for neurodegenerative disorders; Alexion has option to acquire company
- Antisense, Oligonucleotides
- Includes M&A Option
- Intra-Biotech Deal
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.